Investigation of permeation of acyclovir through skin using alaptide

• Autorzy: Cernikova A. , Bobal P. , Bobalova J. , Dohnal J. , Jampilek J.

Identyfikatory

DOI

10.1556/1326.2017.00242

• Języki publikacji: EN

Abstrakty

EN

The investigation deals with the affection of the permeation of acyclovir through full-thickness pig ear skin using a Franz diffusion cell from the donor vehicles of phosphate buffer (pH 7.4) and propylene glycol–water (1:1) using synthesised (S)-8-methyl-6,9-diazaspiro[4.5]decane-7,10-dione, alaptide as a transdermal permeation enhancer. Alaptide was applied in ratio 1:10 (w/w) relative to the amount of acyclovir. At the first hour after application, the permeated amount of acyclovir from propylene glycol–water system, simulating semisolid dosage forms, was ca. four-fold higher than from the formulation without alaptide. Despite that the enhancement ratio of alaptide in a steady state was 1.7, the pseudo-enhancement ratio of alaptide in the time range of first to third hour was 2.3. Both enhancement ratios indicate that alaptide modifies skin structure, while the short-term application of the alaptide formulation seems to be more advantageous.

Słowa kluczowe

EN

Acyclovir; Alaptide; Permeation; Skin; Franz diffusion cell; HPLC determination

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2018
• Tom: Vol. 30, no. 1
• Strony: 62--65
• Opis fizyczny: Bibliogr. 29 poz., rys.

Twórcy

autor

Cernikova A.

• Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Czech Republic

autor

Bobal P.

• Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Czech Republic

autor

Bobalova J.

• Institute of Analytical Chemistry of the CAS, v.v.i., Brno, Czech Republic

autor

Dohnal J.

• Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Czech Republic

autor

Jampilek J.

• Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University, Odbojarov 10, 832 32 Bratislava, Slovakia

Bibliografia

• [1] Jampilek, J. J. Bioequiv. Availab. 2013 , 5 , 233 – 235 .
• [2] Jampilek, J. ; Brychtova, K. Med. Res. Rev. 2012 , 32 , 907 – 947 .
• [3] Kasafirek, E. ; Vanzura, J. ; Krejci, I. ; Krepelka, J. ; Dlabac, A. ; Valchar, M. (inventors). SPOFA – United Pharmaceutical Works & Research Institute for Pharmacy and Biochemistry (assignees). 2,5-Piperazinedione derivs. Belg. P. 897843, 1984 .
• [4] Radl, S. ; Kasafirek, E. ; Krejci, I. Drug Future 1990 , 15 , 445 – 447 .
• [5] Jampilek, J. ; Opatrilova, R. ; Coufalova, L. ; Cernikova, A. ; Dohnal, J. (inventors). University of Veterinary and Pharmaceutical Sciences Brno, Faculty of Pharmacy (assignee). Utilization of alaptide as transdermal penetration modifier in pharmaceutical compositions for human and veterinary applications containing anti-inflammatory drugs and/or antimicrobial chemotherapeutics. WO/2013/020527 A1 , 2013 .
• [6] Opatrilova, R. ; Jampilek, J. ADMET 2014 , 2 , 56 – 62 .
• [7] Cernikova, A. ; Opatrilova, R. ; Jampilek, J. Mil. Med. Sci. Lett. 2014 , 83 , 34 – 39 .
• [8] Cernikova, A. ; Opatrilova, R. ; Bobal, P. ; Jampilek, J. ADMET 2014 , 2 , 248 – 253.
• [9] Cernikova, A. ; Jampilek, J. ADMET 2015 , 3 , 344 – 350 .
• [10] de Clercq, E. ; Field, H. J. British J. Pharmacol. 2006 , 147 , 1 – 11 .
• [11] Drug Bank — Aciclovir, http://www.drugbank.ca/drugs/DB00787 (January 22, 2017) .
• [12] OECD Guidelines for the Testing of Chemicals, Section 4, Test No. 428: Skin Absorption: In Vitro Method, OECD Publishing, Paris, 2004, http://dx.doi.org/10.1787/9789264071087-en (January 22, 2017) .
• [13] WHO. Environmental Health Criteria (EHC 235) — Dermal Absorption. WHO Press, Geneva, Switzerland, 2006, http://www.who.int/ipcs/features/2006/ehc235/en/ (January 22, 2017) .
• [14] Franz, T. J. J. Invest. Dermatol. 1975 , 64 190 – 195 .
• [15] Wu, H. ; Ramachandran, C. ; Weiner, N. D. ; Roessler, B. J. Int. J. Pharm. 2001 , 220 , 63 – 75 .
• [16] Akhtar, N. ; Rehman, M. U. ; Khan, H. M. S. ; Rasool, F. ; Saeed, T. ; Murtaza, G. Trop. J. Pharm. Res. 2011 , 10 , 281 – 288 .
• [17] Panigrahi, L. ; Pattnaik, S. ; Ghosal, S. K. AAPS PharmSciTech 2005 , 6 , E167 – E173 .
• [18] Huang, C. T. ; Tsai, M. J. ; Lin, Y. H. ; Fu, Y. S. ; Huang, Y. B. ; Tsai, Y. H. ; Wu, P. C. Int. J. Nanomedicine 2013 , 2013 , 2295 – 2304 .
• [19] Rhee, Y. S. ; Choi, J. G. ; Park, E. S. ; Chi, S. C. Int. J. Pharm. 2001 , 228 , 161 – 170 .
• [20] Ibrahim, S. A. ; Li, S. K. J. Control. Release 2009 , 136 , 117 – 124 .
• [21] Kasafirek, E. ; Rybak, M. ; Krejci, I. ; Sturs, A. ; Krepela, E. ; Sedo, A. Life Sci. , 1992 , 50 , 187 – 193 .
• [22] Jacobi, U. ; Kaiser, M. ; Toll, R. ; Mangelsdorf, S. ; Audring, H. ; Otberg, N. ; Sterry, W. ; Lademann, J. Skin Res. Technol. 2007 , 13 , 19 – 24 .
• [23] Herkenne, C. ; Naik, A. ; Kalia, Y. N. ; Hadgraft, J. ; Guy, R. H. Pharm. Res. 2006 , 23 , 1850 – 1856 .
• [24] Meyer, W. ; Schwarz, K. ; Neurand, K. T. Curr. Probl. Dermatol. 1978 , 7 , 39 – 52 .
• [25] Yamane, M. A. ; Williams, A. C. ; Barry, B. W. J. Pharm. Pharmacol. 1995 , 47 , 978 – 989 .
• [26] Williams, A. C. ; Barry, B. W. Int. J. Pharm. 1989 , 56 , 43 – 50 .
• [27] Williams, A. C. ; Barry, B. W. Adv. Drug Deliv. Rev. 2004 , 56 , 603 – 618 .
• [28] Trommer, H. ; Neubert, R. H. H. Skin Pharmacol. Physiol. 2006 , 19 , 106 – 121 .
• [29] Barry, B. W. J. Control. Release 1987 , 6 , 85 – 97.

Uwagi

PL

Opracowanie rekordu w ramach umowy 509/P-DUN/2018 ze środków MNiSW przeznaczonych na działalność upowszechniającą naukę (2018).